

5201 General Chapter of Rubber Closures for Packages for Injections

1 Scope

This general chapter specifies the baseline requirements shall be complied with during the manufacturing and application of rubber closures for packages for injections.

This general chapter is applicable to the rubber closures used as part of injection packaging systems.

2 Classification

In addition to the classification in terms of base material, overall structure and pre-use treatment following General Chapter of Rubber Closures for Pharmaceutical Packages (General Chapter 5200), rubber closures for packages for injections could also be classified according to their intended uses and shapes, degree of contact with preparations, and the manner of clinical use.

2.1 In terms of the intended uses and shapes, rubber closures for packages for injections may be classified into rubber stoppers for glass bottles for infusions and glass vials for injections, rubber closures for plastic packaging systems and components for infusions, rubber closures for prefilled syringes and for pen-injectors, etc. Rubber closures for plastic packaging systems and components for infusions may be classified into cap liners for combination caps of plastic packaging systems, rubber stoppers and liners for administration ports of plastic infusion bags, and rubber stoppers for plastic infusion bottles, etc. Rubber closures for prefilled syringes may be classified into plunger stoppers and caps, including needle shields and tip caps. Rubber closures for pen-injectors may be classified into plunger stoppers and septums, which are generally used in combination with aluminum caps.

2.2 According to the degree of being in contact with preparations, the rubber closures may be classified into rubber closures in persistent contact, in transient contact and in indirect contact with preparations in terms of the direct contact time, or classified into rubber closures for packages for aqueous injections and for sterile powders for injection (including freeze-dried preparations for injection) in terms of the contact state.

31 2.3 In terms of the manner of clinical use, the rubber closures may be classified into
32 rubber closures to be pierced and not to be pierced. Rubber closures to be pierced may
33 be further classified into rubber closures singly pierced by infusion sets for intravenous
34 administration (hereinafter referred to as rubber closures pierced by infusion sets), and
35 singly or multiply pierced by hypodermic needles for product dissolution or transfer
36 (hereinafter referred to as rubber closures singly or multiply pierced by hypodermic
37 needles).

38 **3 Overall Requirements**

39 Rubber closures for packages for injections shall comply with the following
40 requirements during the periods of manufacturing and use.

41 Rubber closures for packages for injections shall comply with the relevant
42 provisions specified in Overall Requirements of General Chapter of Rubber Closures
43 for Pharmaceutical Packages (General Chapter 5200). For wash-free and ready-to-use
44 rubber closures for packages for injections, validation of the processes of
45 depyrogenation and sterilization (when applicable) shall be conducted.

46 For the rubber closures for freeze-dried preparations, attention should be paid to
47 the structure design, such as the position and size of the positioning element, which
48 should not adversely affect the sealing performance of the rubber closures. Attention
49 should be paid to residual moisture of the rubber closures, on which the possible effects
50 of the formulations and processes should be evaluated when necessary. Appropriate
51 techniques could be used to assess the water content and the effectiveness of the drying
52 process conditions, and water content of rubber closures shall be effectively controlled
53 before use following the stability requirements of the pharmaceutical products.

54 For the design of rubber closures for prefilled syringes and for pen-injectors, the
55 different functional requirements of manual or automatic use should be taken into
56 account.

57 **4 Quality Control**

58 For rubber closures for packages for injections, the relevant tests specified in
59 Quality Control of General Chapter of Rubber Closures for Pharmaceutical Packages
60 (General Chapter 5200) and the following tests shall be performed

61 4.1 Physicochemical Tests

62 4.1.1 Water content. Applied to ready-to-use rubber closures for packages for
63 freeze-dried preparations for injection. When necessary, perform the test according to
64 Method II of Determination of Water for Rubber Closures (General Chapter 4221), and
65 the results shall comply with the relevant specifications of enterprise standards or
66 quality agreements.

67 4.1.2 Silicone oil on the surface. Applied to rubber closures for packages for injections
68 which are in direct contact with pharmaceutical products when whose quality could be
69 affected by the silicone oil. When necessary, perform the test according to
70 Determination of Silicone Oil on the Surface of Rubber Closures (General Chapter
71 4222), and the results shall comply with the relevant specifications of enterprise
72 standards or quality agreements.

73 4.2 Clinical Use Performance Tests

74 Including but not limited to the tests specified in this general chapter,
75 corresponding tests shall be carried out according to the production processes and
76 clinical use of the pharmaceutical products. If rubber closures would be penetrated by
77 hypodermic needles and infusion sets simultaneously when in clinical use,
78 corresponding tests of rubber closures pierced by infusion sets and pierced by
79 hypodermic needles are carried out respectively when necessary, and all results shall
80 comply with the relevant requirements.

**81 4.2.1 Rubber Stoppers for Glass Bottles for Infusion and Glass Vials for
82 Injections**

83 The following tests are carried out for rubber stoppers for glass bottles for infusion
84 and glass vials for injections. For rubber stoppers for packages for freeze-dried
85 preparations, the following tests are carried out after the samples were pretreated under
86 freezing conditions specified in enterprise standards or quality agreements.

87 4.2.1.1 Fragmentation. Applied to the rubber stoppers pierced by infusion sets. Perform
88 the test according to Method I of Test for Fragmentation of Closures and Seals for
89 Parenteral Preparations (General Chapter 4016). The number of observed particles is
90 not more than 20.

91 Applied to the rubber stoppers pierced by hypodermic needles. Perform the test
92 according to Method II of Test for Fragmentation of Closures and Seals for Parenteral
93 Preparations (General Chapter 4016). The number of observed particles is not more
94 than 5.

95 4.2.1.2 Penetration force. Applied to the rubber stoppers pierced by infusion sets.
96 Perform the test according to Method I of Test for Penetrability of Closures and Seals
97 for Parenteral Preparations (General Chapter 4015). The average of all test samples is
98 not more than 75 N and all test samples does not exceed 80 N, and no rubber stopper is
99 pushed into the bottle during the piercing.

100 Applied to the rubber stoppers pierced by hypodermic needles. Perform the test
101 according to Method II of Test for Penetrability of Closures and Seals for Parenteral
102 Preparations (General Chapter 4015), and the penetration force for all test samples does
103 not exceed 10 N.

104 4.2.1.3 Spike retention and sealability Capacity. Applied to the rubber stoppers pierced
105 by infusion sets. Take 10 samples pretreated according to Method I of Test for
106 Penetrability of Closures and Seals for Parenteral Preparations (General Chapter 4015),
107 and 10 matched bottles for injections filled to the nominal volume with water, then
108 crimp the matched aluminum caps or aluminum-plastic caps. Use the metal spikes
109 described in Method I of Test for Penetrability of Closures and Seals for Parenteral
110 Preparations (General Chapter 4015) to vertically pierce the marked area until
111 complete penetration is achieved. Position the bottles with the bottom end up and
112 attach a mass of 0.5 kg to each spike. Spikes shall be retained in the closures for 4h
113 and no liquid leakage shall be observed at the puncture sites of the stoppers.

114 4.2.1.4 Self-sealing Capacity. Applied to rubber stoppers multiply pierced by
115 hypodermic needles, and need to be performed only after being fitted with other
116 assembly components. Take 10 samples pretreated according to Method II of Test for
117 Penetrability of Closures and Seals for Parenteral Preparations (General Chapter
118 4015). Take 10 matched vials for injections filled to the nominal volume with water,
119 then fit the above rubber stoppers and secure with the matched fasteners. Use injection
120 needles defined in Method II of Test for Penetrability of Closures and Seals for

121 Parenteral Preparations (General Chapter 4015) to vertically pierce the different
122 puncture sites of each stopper 3 times, changing a new needle after every 10 punctures.
123 Immerse the above test samples bottom end up in 0.1% methylene blue solution in a
124 container with a vacuum pump, reduce the pressure by 27kPa and hold for 30 min, then
125 restore to atmospheric pressure and hold for another 30 min. Take the test samples out,
126 rinse the outsides of the vials with water. Any trace of methylene blue solution is
127 observed in none of the containers. For rubber stoppers specified the test of self-sealing
128 capacity, the test of Sealability of Closures for Containers is generally not required
129 further.

130 4.2.1.5 Sealability of closures for containers. Applied to the rubber stoppers singly
131 pierced by hypodermic needles, and need to be performed only after being fitted with
132 other assembly components. Take 10 samples pretreated according to Method II of Test
133 for Penetrability of Closures and Seals for Parenteral Preparations (General Chapter
134 4015). Take 10 matched vials for injections filled to the nominal volume with water,
135 then fit the above rubber stoppers and secure with the matched fasteners. Immerse the
136 above test samples bottom end up in 0.1% methylene blue solution in a container with a
137 vacuum pump, reduce the pressure by 27kPa and hold for 30 min, then restore to
138 atmospheric pressure and hold for another 30 min. Take the test samples out, rinse the
139 outsides of the vials with water. Any trace of methylene blue solution is observed in
140 none of the vials. If direct observation is impossible, the solution may be taken out by a
141 suitable method and inspected visually. The solution does not appear blue.

142 **4.2.2 Rubber Closures for Plastic Packaging Systems and Components for** 143 **Infusions**

144 The following tests are carried out for cap liners for combination caps of plastic
145 packaging systems. For other rubber closures for plastic packaging systems and
146 components for infusions, taking account of the characteristics of packaging systems
147 and the manners of clinical use, the relevant clinical use performance tests specified in
148 enterprise standards or quality agreements shall be complied with.

149 4.2.2.1 Fragmentation. Perform the test according to Method III of Test for
150 Fragmentation of Closures and Seals for Parenteral Preparations (General Chapter 4016)

151 (The plastic packaging systems for infusions may act as the supporting device. Fit the
152 cap liners to matched plastic infusion containers separately, fill the containers to the
153 nominal volume with water, seal and sterilize according to the pretreatment conditions.).

154 The number of observed particles shall be not more than 20.

155 4.2.2.2 Penetration force. Perform the test according to Method III of Test for
156 Penetrability of Closures and Seals for Parenteral Preparations (General Chapter 4015)

157 (The plastic packaging systems for infusions may act as the supporting device. Fit the
158 cap liners to matched plastic infusion containers separately, fill the containers to the
159 nominal volume with water, seal and sterilize according to the pretreatment conditions.).

160 The average of all test samples are not more than 75 N and all test samples do not
161 exceed 80 N.

162 4.2.2.3 Spike retention and sealability. Need to be performed only after the rubber
163 closures are fitted with other assembly components. Fit 10 cap liners to matched plastic
164 infusion containers separately, fill the containers to the nominal volume with water and
165 seal. Use the plastic spike described in Method III of Test for Penetrability of Closures
166 and Seals for Parenteral Preparations (General Chapter 4015) to vertically pierce the
167 marked area until complete penetration is achieved. Position the containers with the
168 bottom end up and attach a mass of 0.3 kg to each spike. Spikes shall be retained in the
169 closures for 4h and no liquid leakage shall be observed at the puncture sites of the
170 closures.

171 **4.2.3 Rubber Closures for Prefilled Syringes**

172 Only after rubber closures for prefilled syringes are subassembled or assembled
173 with other assembly components, corresponding tests need to be performed, and the
174 results shall comply with the relevant specifications of the General Chapter of Prefilled
175 Syringes(General Chapter 5510).

176 **4.2.4 Rubber Closures for Pen-Injectors**

177 Only after rubber closures for pen-injectors are subassembled or assembled with
178 other assembly components, corresponding tests need to be performed, and the results
179 shall comply with the relevant specifications of the General Chapter of Cartridge
180 Systems for Pen-Injectors(General Chapter 5520).

181 **4.3 Other Tests**

182 4.3.1 Particulate matter. Applied to wash-free and ready-to-use rubber closures, and
 183 tested when necessary. Perform the test according to Determination of Particulate
 184 Matter for Pharmaceutical Packaging Materials and Containers (General Chapter 4206),
 185 and the results shall comply with the specifications in the following table.

| packaging System/Assembly | Rubber Closures | Limit (particles/mL) | |
|--|--------------------|----------------------|-----------------|
| | | 10 µm and above | 25 µm and above |
| Packaging System for Injections | Stopper | 30 | 3 |
| Packaging System for Sterile Powders for Injections | Stopper | 60 | 6 |

186 4.3.2 Bioburden. When necessary, perform the test of bioburden according to
 187 Guideline on Microbiological Testing of Pharmaceutical Packaging Materials
 188 (Guideline 9653), and the results shall comply with the relevant specifications of
 189 enterprise standards or quality agreements. For rubber stoppers for packages for
 190 injections specified the test of sterility, the test of Bioburden is generally not required
 191 further.

192 4.3.3 Sterility. Applied to ready-to-use rubber closures. When necessary, perform the
 193 test of sterility according to Guideline on Microbiological Testing of Pharmaceutical
 194 Packaging Materials (Guideline 9653), and the results shall comply with the
 195 specifications.

196 4.3.4 Bacterial endotoxins or pyrogens. Applied to wash-free and ready-to-use rubber
 197 closures. When necessary, perform the test of bacterial endotoxins according to
 198 Guidelines for the Application of Bacterial Endotoxin Test (Guideline 9251), and the
 199 results shall comply with the relevant specifications directed in the specific monograph
 200 of pharmaceutical products. If the pharmaceutical product and its relevant
 201 specifications cannot be defined, the results of bacterial endotoxin shall be less than
 202 0.25 EU/mL, or take an appropriate amount of the test solution to perform the test of
 203 pyrogens according to Test for Pyrogens (General Chapter 1142), and the results shall
 204 comply with the specifications.

205 **5 Packaging and Storage**

206 The packaging materials in direct contact with rubber closures shall comply with

207 the relevant requirements of pharmaceutical packages. The packages for ready-to-use
208 rubber closures should be resistance to the sterilization processes applied, and cause
209 no adverse influence on the effects of sterilization. The sealed packages shall be of
210 enough integrity, and the primary and secondary packaging as a whole should meet the
211 requirements for protection performance during the transportation and storage. The
212 packages for ready-to-use rubber closures should meet the requirements of quality
213 management and convenience of pharmaceutical production.

214 The rubber closures should be stored in the dry, clean and well-ventilated indoor
215 environment.

Prepared by: Shanghai Food and Drug Packaging Materials Testing Institute Tel:
021-50798250

Participants: Sichuan Institute for Drug Control (Sichuan Center for Medical Device
Testing), Jiangsu Best New Medical Material Co, Ltd., National Institutes for Food and
Drug Control, Shanghai Institute for Food and Drug Control, Shandong Institute for
Medical Device and Drug Packaging, Jiangxi Institute for Drug Control, Zhejiang
Institute for Food and Drug Control, China Pharmaceutical Packaging Association